Alzheimer's marker linked to subtle differences in older adults
An observational study of 644 older adults linked an elevated Alzheimer's blood marker to subtle differences in thinking, behavior and body function.
Cross-sectional study
Limit: Only 93 participants had both elevated p-tau217 and unimpaired cognition
Edited by Boris Djordjevic · AgingResearch.News
Researchers assembled an observational cohort of 644 older adults who reported intact thinking abilities. Participants had no diseases affecting the body as a whole or the nervous system, and their risk factors were medically managed.
P-tau217, a blood marker of Alzheimer's disease, was elevated in 20%, and 93 of these participants were cognitively unimpaired. This biomarker-defined subgroup showed subtle differences in thinking and behavior. Modest differences in measures of body function remained within clinical reference ranges. Reported histories of modifiable risk factors were not associated with p-tau217 when those factors were effectively managed. A proof-of-concept artificial intelligence tool combining routine clinical information improved identification of people with high p-tau217 compared with screening based on thinking abilities alone.
Why it matters
For Alzheimer's disease, the authors support screening across several areas of health to help identify people for biomarker testing before obvious cognitive impairment.
Caveats
These observational findings describe group-level differences and cannot establish cause and effect. The preprint has not been peer-reviewed, and its cohort excluded people with systemic or neurological diseases.
The paper
The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, Jerusalem, Israel
bioRxiv, Oct 30, 2026, Open access, CC BY-NC-ND, Preprint, not peer-reviewed
